ABOUT GULSINE
The scientific company behind A2P2
Gulsine is a specialist materials-science company building the infrastructure for mechanism-driven product-lifetime decisions. Its core asset is A2P2: a patented framework and protected platform for determining material-specific activation behaviour, acceleration factors and study designs.
THE PEOPLE BEHIND A2P2

Dr Nazli Gulsine Ozdemir
CEng FIMMM
FOUNDER AND SCIENTIFIC LEAD
Dr Ozdemir has more than fifteen years of experience in polymer ageing, medical-device materials and product-lifetime assessment. She leads ASTM work relating to accelerated ageing and experimental Q₁₀ determination and contributes as a UK expert within ISO medical-device lifecycle work.
Her work connects first-principles materials science with the practical demands of R&D, quality systems, regulatory submissions and commercial product release.
“The reasonable man adapts himself to the world: the unreasonable one persists in trying to adapt the world to himself. Therefore all progress depends on the unreasonable man.”George Bernard Shaw
30 productsmanaged from concept to product release, from bioreactors to filtration systems
Global instructionher accelerated-ageing validation strategy for biopharmaceutical devices was adopted by Sartorius in 2023
INDUSTRYSartoriusSolvayZotefoamsFNSS
ACADEMIAUoBKU LondonSabancı UniversityMETU

Prof Steven Abbott
A2P2 APPLICATIONS
Prof Abbott has a PhD in Chemistry from work in Oxford and Harvard, and did a post-doc with Nobel Prize winner J-M Lehn in Strasbourg. He worked in industry at ICI and as Research Director at a coatings company, and was made Visiting Professor at the School of Mechanical Engineering at the University of Leeds.
Now independent, he brings good science to life through software, apps and app-linked books, and works with corporations around the world as a troubleshooter using his own app-based approach.
WHAT GULSINE BUILDS
A2P2 is designed to become an internal enterprise capability—not a dependency on repeated one-off consulting.
01
Licensethe framework
02
Establisha foundational programme around a lead product
03
Transferthe methods into their laboratories
04
Builda governed knowledge base across their portfolio
IP PORTFOLIO
Patented in the UK, under examination in Europe, pending in the US
1
GRANTED
2
ALLOWED FOR GRANT
1
UNDER EXAMINATION
3
PENDING

